-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent news, another biopharmaceutical company "Zheji" Sci-tech Innovation Board terminates its IPO: The Shanghai Stock Exchange has decided to terminate the initial public offering of Hangzhou Suoyuan Bio-Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Suoyuan Bio") and listed on the Sci-tech Innovation Board.
Listing review
.
According to the data, Suoyuan Bio is focused on the field of anti-tumor.
By introducing new drugs that have been clinically verified in Phase II and III and are effective for some patients, the company has a unique biomarker discovery platform that can be used to find independently verified drugs.
Predict biomarkers of drug efficacy, and then re-launch international multi-center clinical trials guided by biomarkers to develop innovative drugs for the global market
.
Among them, DB102 is the original innovative drug introduced from Eli Lilly in 2014.
This product has the direct effect of inducing tumor cell death and hindering tumor cell proliferation.
It is a potent and selective PKCβ inhibitor.
At present, there is no PKC inhibitor in the world.
Target's new drugs are launched on the market
.
As the company's core products have not yet entered the commercialization stage and product sales revenue has not yet been formed, Suoyuan Biological continues to lose money
.
From 2018 to 2020, the company achieved attributable net profits of -103 million yuan, -134 million yuan and 223 million yuan, respectively.
During the reporting period, the company's research and development expenses were 82.
958 million yuan, 112 million yuan and 173 million yuan, respectively
.
Before applying for the IPO of the Science and Technology Innovation Board, Suoyuan Bio-Bio has completed multiple rounds of financing with a total of more than 1 billion yuan
.
It is reported that the company originally planned to publicly issue no more than 129,371,100 shares, and originally planned to raise 1.
634 billion yuan for innovative drug research and development projects and marketing network construction projects
.
Judging from the history of IP0, Suoyuan Biotechnology submitted the IPO application on the Sci-tech Innovation Board on June 30, 2021.
It has been nearly 5 months until now, and the IPO application journey on the Sci-Tech Innovation Board has ended
.
Regarding the reasons for the termination, the company replied to the relevant media that recently the company has made a series of progress in the R&D and operation of multiple pipelines, and the capital operation and business development also need to be adjusted in time, so it actively withdrew the science and technology board.
Application for listing
.
Looking back at 2021, the only biopharmaceutical company on the "Zheji" Sci-tech Innovation Board to terminate the IPO is Suoyuan Bio
.
On March 22, 2021, Suzhou Jingyun Pharmaceutical Technology Co.
, Ltd.
was suspended for deliberation by the Shanghai Stock Exchange's Science and Technology Innovation Board Listing Committee.
The Listing Committee required the company to combine its core technology, research and development capabilities and competitive advantages to explain its own information disclosure on science and technology attributes compliance with the relevant requirements of the current cloud of drug crystal state is not updated; in September this year, the number of companies is terminated IPO audit, including Shanghai Hai and drugs, because Shanghai Ji Kaiji medicine
.
In addition, pharmaceutical companies such as Aopu Biotechnology and Beijing Tianguangshi Biotechnology have also reported the termination of the IPO of the Science and Technology Innovation Board
.
According to incomplete statistics in the industry, as of now, at least 16 biomedical companies have broken the Sci-tech Innovation Board
.
According to the industry, five hurdles need to be passed for IPO on the Science and Technology Innovation Board.
Calculated from the acceptance, it needs to go through several links, including inquiry, listing committee meeting, submission of registration, and entry into force of registration
.
The Science and Technology Innovation Board has always regarded "hard technology" as a key support direction
.
It is not difficult to find from the reasons for the termination of the above-mentioned pharmaceutical companies that the regulatory authorities pay more attention to the company’s scientific and technological innovation attributes, environmental protection, internal control, and core technologies.
Among them, the core technology and sustainable operation capabilities are more concerned by the regulatory authorities and the companies that have been rejected Such problems are quite prominent
.
This also means that biopharmaceutical companies' Sci-tech Innovation Board IPOs need to focus on these issues
.
"Especially in terms of early-stage risk control, due to the long R&D cycle of new drug investment and large capital investment, biopharmaceutical companies need to do a good job in this regard
.
"
, Ltd.
(hereinafter referred to as "Suoyuan Bio") and listed on the Sci-tech Innovation Board.
Listing review
.
According to the data, Suoyuan Bio is focused on the field of anti-tumor.
By introducing new drugs that have been clinically verified in Phase II and III and are effective for some patients, the company has a unique biomarker discovery platform that can be used to find independently verified drugs.
Predict biomarkers of drug efficacy, and then re-launch international multi-center clinical trials guided by biomarkers to develop innovative drugs for the global market
.
Among them, DB102 is the original innovative drug introduced from Eli Lilly in 2014.
This product has the direct effect of inducing tumor cell death and hindering tumor cell proliferation.
It is a potent and selective PKCβ inhibitor.
At present, there is no PKC inhibitor in the world.
Target's new drugs are launched on the market
.
As the company's core products have not yet entered the commercialization stage and product sales revenue has not yet been formed, Suoyuan Biological continues to lose money
.
From 2018 to 2020, the company achieved attributable net profits of -103 million yuan, -134 million yuan and 223 million yuan, respectively.
During the reporting period, the company's research and development expenses were 82.
958 million yuan, 112 million yuan and 173 million yuan, respectively
.
Before applying for the IPO of the Science and Technology Innovation Board, Suoyuan Bio-Bio has completed multiple rounds of financing with a total of more than 1 billion yuan
.
It is reported that the company originally planned to publicly issue no more than 129,371,100 shares, and originally planned to raise 1.
634 billion yuan for innovative drug research and development projects and marketing network construction projects
.
Judging from the history of IP0, Suoyuan Biotechnology submitted the IPO application on the Sci-tech Innovation Board on June 30, 2021.
It has been nearly 5 months until now, and the IPO application journey on the Sci-Tech Innovation Board has ended
.
Regarding the reasons for the termination, the company replied to the relevant media that recently the company has made a series of progress in the R&D and operation of multiple pipelines, and the capital operation and business development also need to be adjusted in time, so it actively withdrew the science and technology board.
Application for listing
.
Looking back at 2021, the only biopharmaceutical company on the "Zheji" Sci-tech Innovation Board to terminate the IPO is Suoyuan Bio
.
On March 22, 2021, Suzhou Jingyun Pharmaceutical Technology Co.
, Ltd.
was suspended for deliberation by the Shanghai Stock Exchange's Science and Technology Innovation Board Listing Committee.
The Listing Committee required the company to combine its core technology, research and development capabilities and competitive advantages to explain its own information disclosure on science and technology attributes compliance with the relevant requirements of the current cloud of drug crystal state is not updated; in September this year, the number of companies is terminated IPO audit, including Shanghai Hai and drugs, because Shanghai Ji Kaiji medicine
.
In addition, pharmaceutical companies such as Aopu Biotechnology and Beijing Tianguangshi Biotechnology have also reported the termination of the IPO of the Science and Technology Innovation Board
.
According to incomplete statistics in the industry, as of now, at least 16 biomedical companies have broken the Sci-tech Innovation Board
.
According to the industry, five hurdles need to be passed for IPO on the Science and Technology Innovation Board.
Calculated from the acceptance, it needs to go through several links, including inquiry, listing committee meeting, submission of registration, and entry into force of registration
.
The Science and Technology Innovation Board has always regarded "hard technology" as a key support direction
.
It is not difficult to find from the reasons for the termination of the above-mentioned pharmaceutical companies that the regulatory authorities pay more attention to the company’s scientific and technological innovation attributes, environmental protection, internal control, and core technologies.
Among them, the core technology and sustainable operation capabilities are more concerned by the regulatory authorities and the companies that have been rejected Such problems are quite prominent
.
This also means that biopharmaceutical companies' Sci-tech Innovation Board IPOs need to focus on these issues
.
"Especially in terms of early-stage risk control, due to the long R&D cycle of new drug investment and large capital investment, biopharmaceutical companies need to do a good job in this regard
.
"
